NUCALA POWDER FOR SOLUTION FOR INJECTION 100mg

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

**Dosage and Administration** Pharmaceutical form: Powder for solution for infusion. _NUCALA_ should be administered by a health care professional. _NUCALA_ should be prescribed by physicians experienced in the diagnosis and treatment of severe eosinophilic asthma. Following reconstitution, _NUCALA_ should only be administered as a subcutaneous injection (e.g. upper arm, thigh, or abdomen) (see _Use and Handling_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Populations** **Adults and Adolescents (12 years and older)** The recommended dose is 100 mg of _NUCALA_ administered by subcutaneous (SC) injection once every 4 weeks. **Children (up to 12 years of age)** The safety and efficacy of _NUCALA_ have not been established in children less than 12 years of age. **Elderly (65 years or older)** No dosage adjustment is recommended in patients 65 years or older (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Renal Impairment** Dose adjustments in patients with renal impairment are unlikely to be required (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Hepatic Impairment** Dose adjustments in patients with hepatic impairment are unlikely to be required (see _Pharmacokinetics – Special Patient Populations_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).